Literature DB >> 21649526

Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma.

Hee Jin Lee1, Se Jin Jang, Sung-Min Chun, Seung-Il Park, Dong Kwan Kim, Jene Choi.   

Abstract

Pulmonary sclerosing hemangioma (SH) is an unusual tumor of pneumocytic origin. Morphologically, SH can mimic pulmonary adenocarcinomas. Here, the authors compared genetic and epigenetic aberrations in SH with those in pulmonary adenocarcinoma. Clinicopathologic characteristics, microsatellite alterations, and CpG island methylation were analyzed in pulmonary SHs (n = 24) and adenocarcinomas (n = 34) to compare their patterns of molecular abnormalities. SHs were also analyzed immunohistochemically to characterize the expression status of proteins involved in basic biologic processes. The clinical presentation of SH cases was generally benign. Both cell types of SH stained positive for thyroid transcription factor 1 (TTF-1), epithelial membrane antigen (EMA), β-catenin, E-cadherin, and vascular endothelial growth factor (VEGF). Allelic imbalances in D3S1283, D3S1234, D3S1300, D3S1285, TP53, D17S938, and D9S179 were less frequent in SH than in adenocarcinoma; rates of allelic imbalances in D20S170 and D21S1446 were not significantly different. In SH, CpG island methylation frequencies of p16(INK4a) (0.0%) and RASSF1A (12.5%) were significantly lower than those in adenocarcinoma (29.4% and 38.2%, respectively); the frequencies of HOX D9, D11, and D13 gene methylation in SH were 37.5%, 33.3%, and 33.3%, respectively. The results show that pulmonary SH and adenocarcinoma share similar genetic and epigenetic aberrations, but also exhibit significant differences, especially in tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21649526     DOI: 10.3109/01902148.2011.577267

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  5 in total

1.  Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.

Authors:  Seung-Hyun Jung; Min Sung Kim; Sung-Hak Lee; Hyun-Chun Park; Hyun Joo Choi; Leeso Maeng; Ki Ouk Min; Jeana Kim; Tae In Park; Ok Ran Shin; Tae-Jung Kim; Haidong Xu; Kyo Young Lee; Tae-Min Kim; Sang Yong Song; Charles Lee; Yeun-Jun Chung; Sug Hyung Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

2.  Pulmonary sclerosing pneumocytoma: Cytomorphology and immunoprofile.

Authors:  Zahra Maleki; Stephanie Muller; Lester Layfield; Momin T Siddiqui; Natasha Rekhtman; Liron Pantanowitz
Journal:  Cancer Cytopathol       Date:  2020-02-05       Impact factor: 4.264

3.  New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis.

Authors:  Giovanna E Carpagnano; Donato Lacedonia; Elisabetta Crisetti; Domenico Martinelli; Maria P Foschino-Barbaro
Journal:  J Cancer       Date:  2016-11-25       Impact factor: 4.207

4.  [Analysis of Clinical Characteristics of 35 Cases 
of Pulmonary Sclerosing Pneumocytoma].

Authors:  Xiaojing Liu; Zhihao Huang; Jianyong Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-12-20

5.  Transcript analysis reveals a specific HOX signature associated with positional identity of human endothelial cells.

Authors:  Mark Toshner; Benjamin J Dunmore; Eoin F McKinney; Mark Southwood; Paola Caruso; Paul D Upton; John P Waters; Mark L Ormiston; Jeremy N Skepper; Gerard Nash; Amer A Rana; Nicholas W Morrell
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.